Additionally, clinical trials (NCT02746081) are underway to test IDH inhibitors in gliomas (49, 50) as the IDH mutation can be found in 17–48% of adults with GC (1, 13, 39). This evidence concerns the gene IDH1 and central nervous system cancer.